Final 3 year results from the landmark HORIZONS-AMI trial published in the Lancet
Data from the landmark HORIZONS-AMI clinical trial demonstrated that the administration of the anticoagulant medication bivalirudin enhanced survival compared to the use of heparin plus a glycoprotein (GP) IIb/IIIa inhibitor ...
Jun 13, 2011
0
1